Sarepta Therapeutics, Inc. SRPT Business Segments — Net Income Loss

Similar metrics at other companies

NBT

NBTBAll Other Segments — Net Income Loss

$926K-40.5%

UFPIAll Other Segments — Profit Loss

$3.55M+42.0%

RUSHBAll Other Segments — Profit Loss

-$89K+7.3%

QCRHAll Other Segments — Net Income Loss

$33.85M+28.2%

SEBAll Other Segments — Profit Loss

$5.5M+4.8%

OGEAll Other Segments — Profit Loss

-$7.7M+7.2%

Questions, answered.

What is Sarepta Therapeutics, Inc.'s business segments — net income loss?

Sarepta Therapeutics, Inc. (SRPT) reported business segments — net income loss of $330.96M in Q1 2026.

How has Sarepta Therapeutics, Inc.'s business segments — net income loss changed year-over-year?

Sarepta Therapeutics, Inc.'s business segments — net income loss increased by 174.0% year-over-year, from -$447.51M to $330.96M.

What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — net income loss?

Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — net income loss has grown at a 0.5% compound annual growth rate (CAGR), from -$703.49M to -$713.41M.

What does business segments — net income loss mean?

The final bottom-line financial result for the segment after all revenues, operating expenses, taxes, and non-operating items are accounted for. This metric serves as the primary indicator of the segment's overall profitability and economic viability. It captures the net impact of all business activities within this specific segment.